InvestorNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering

Actuate Therapeutics (NASDAQ: ACTU), a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers, recently announced the closing of its previously announced initial offering. The offering comprised 2,800,000 shares of the company’s common stock at a price of $8.00 per unit to the public, raising a total of $22,400,000 in gross proceeds before deductions. In addition, the company has granted a 30-day option to the underwriters to purchase up to 420,000 additional shares, representing 15% of the shares sold in the offering, solely to cover over-allotments, if any, at the initial public offering price, less the underwriting discounts and commissions. The company’s shares began trading on August 13, 2024, on the Nasdaq Global Market under the ticker symbol ACTU.

To view the full article, visit https://ibn.fm/ebDCK

About Actuate Therapeutics, Inc.

Actuate is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3 inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DDR pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of NF-kB and regulates multiple immune checkpoints and immune cell function. For more information about the company, visit https://actuatetherapeutics.com.

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

The post InvestorNewsBreaks – Actuate Therapeutics, Inc. (NASDAQ: ACTU) Closes on $22.4M Initial Public Offering appeared first on Invezz